A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy with Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) with Digoxin in Patients with Resectable Pancreatic Cancer
Categories (click each to see list of all clinical trials associated with that category): GI (ONC)
Current Status: Open
Phase: II (Cancer Control)
Principal Investigator: Grem, Jean
Contact Information:
Brandie Booker, RN
402-559-8197
brandie.booker@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT04141995?term=NCT04141995&rank=1
Summary
Primary Objectives
1. To assess the feasibility and safety of neoadjuvant chemotherapy with FOLFIRINOX given with digoxin in patients with resectable pancreatic cancer. The regimen would considered worthy or further investigation, if 14 of the 20 or more of patients are able to undergo resection.
Secondary Objectives
1. To evaluate the efficacy of neoadjuvant chemotherapy with FOLFIRINOX given with digoxin in patients with resectable pancreatic cancer